Inhibikase Therapeutics (IKT) Receivables - Other (2021)

Inhibikase Therapeutics (IKT) reported Receivables - Other of $217482.0 for Q3 2021, down 62.92% quarter-over-quarter from $586581.0 in Q2 2021.

Inhibikase Therapeutics (IKT) Receivables - Other (2021) Analysis & Trends

Inhibikase Therapeutics (IKT) has 1 years of Receivables - Other data on file, last reported at $217482.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Inhibikase Therapeutics	285.17 Mn	114.80 Mn	-

Download Data